tiprankstipranks
Trending News
More News >

Heron Therapeutics Appoints Mark Hensley as COO

Story Highlights
Heron Therapeutics Appoints Mark Hensley as COO

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Heron Therapeutics ( (HRTX) ).

On April 28, 2025, Heron Therapeutics announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley, who has over fifteen years of experience in the pharmaceutical industry, previously held senior leadership roles at Veloxis Pharmaceuticals. His appointment is expected to play a pivotal role in Heron’s growth, with his extensive operational and leadership experience ensuring efficiency and compliance as the company advances its strategic priorities. Mr. Hensley’s compensation includes a base salary, a cash bonus, and inducement awards in the form of stock options and restricted stock units, which are designed to align his interests with the company’s performance goals.

Spark’s Take on HRTX Stock

According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.

Heron Therapeutics’ stock score is primarily impacted by financial instability, with consistent revenue growth overshadowed by profitability challenges and high leverage. Technical indicators suggest weak momentum. The positive earnings call sentiment due to profitability and revenue growth is a major positive factor, but ongoing competition and cash flow issues remain significant concerns.

To see Spark’s full report on HRTX stock, click here.

More about Heron Therapeutics

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving patient care through the development and commercialization of therapeutic innovations. The company aims to advance the standard-of-care for acute care and oncology patients through its advanced science, patented technologies, and innovative drug discovery and development approach.

YTD Price Performance: 45.62%

Average Trading Volume: 1,647,881

Technical Sentiment Signal: Hold

Current Market Cap: $354.9M

Learn more about HRTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1